Finance

Lists
1177:HKG
Sino Biopharmaceutical Ltd
HK$4.94
-1.69%
(-0.085) 1D
Aug 3, 4:08:10 PM GMT+8  ·   HKD
All symbols
SymbolPriceChange% Change
Generating top insights for 1177...
Open
HK$5.06
High
HK$5.08
Low
HK$4.88
Mkt. cap
124.82B
Avg. vol.
111.63M
Volume
58.18M
Dividend
2.02%
Quarterly dividend
HK$0.03
P/E ratio
32.82
52-wk high
HK$9.12
52-wk low
HK$4.19
EPS
HK$0.15
Shares outstanding
12.64B
No. of employees
17K
Open
HK$5.06
High
HK$5.08
Low
HK$4.88
Mkt. cap
124.82B
Avg. vol.
111.63M
Volume
58.18M
Dividend
2.02%
Quarterly dividend
HK$0.03
P/E ratio
32.82
52-wk high
HK$9.12
52-wk low
HK$4.19
EPS
HK$0.15
Shares outstanding
12.64B
No. of employees
17K
News stories
From sources across the web
Profile
Intuitive Surgical, Inc. is an American biotechnology company that develops, manufactures, and markets robotic products designed to improve clinical outcomes of patients through minimally invasive surgery, most notably with the da Vinci Surgical System. The company is part of the Nasdaq-100, S&P 100 and S&P 500. As of 31 December 2021, Intuitive Surgical had an installed base of 6,730 da Vinci Surgical Systems, including 4,139 in the U.S., 1,199 in Europe, 1,050 in Asia, and 342 in the rest of the world. Intuitive Surgical first appeared on the Fortune 500 in 2024 at number 497; in 2025 the company rose to number 459 overall and ranked 43rd within the healthcare sector. Wikipedia
About Sino Biopharmaceutical Ltd
CEODavid J. Rosa
Employees17K
Founded1995
HeadquartersSunnyvale, California, United States
SectorMedical device
Previous reportsAll values in CNY
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in CNY
Mar 2025
Jun 2025
Sep 2025
Dec 2025
Revenue
8.79B
8.79B
7.13B
7.13B
Cost of goods sold
1.54B
1.54B
1.31B
1.31B
Cost of revenue
1.54B
1.54B
1.31B
1.31B
Research and development expenses
-
-
2.93B
2.93B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
3.77B
3.77B
2.80B
2.80B
Operating expense
5.54B
5.54B
4.38B
4.38B
Total operating expenses
7.08B
7.08B
5.69B
5.69B
Operating income
1.70B
1.70B
1.44B
1.44B
Other non operating income
40.54M
40.54M
97.99M
97.99M
EBT including unusual items
2.98B
2.98B
488.22M
488.22M
EBT excluding unusual items
2.72B
2.72B
1.55B
1.55B
Income tax expense
490.66M
490.66M
323.77M
323.77M
Effective tax rate
16.45%
16.45%
66.32%
66.32%
Other operating expenses
1.77B
1.77B
-1.35B
-1.35B
Net income
1.69B
1.69B
-522.62M
-522.62M
Net profit margin
-
-
-
-
Earnings per share
-
-
-
-
Interest and investment income
989.64M
989.64M
196.36M
196.36M
Interest expense
-61.60M
-61.60M
-77.56M
-77.56M
Net interest expenses
928.03M
928.03M
118.80M
118.80M
Depreciation and amortization charges
-
-
-
-
EBITDA
1.97B
1.97B
1.66B
1.66B
Gain or loss from assets sale
-
-
-5.58M
-5.58M
AI content may include mistakes. Learn more

Research

What's on your mind?
What's going on with the markets today?
Explore what’s possible
Create a portfolio
Create a task
Deep Search
AI content may include mistakes. Learn more
Google apps